0.89%| Prev Close: | 98.67 |
|---|---|
| Open: | 100.00 |
| Bid: | 101.10 x 100 |
| Ask: | 101.65 x 100 |
| 1y Target Est: | 117.41 |
| Beta: | 0.63 |
| Next Earnings Date: | N/A |
| Day's Range: | 100.00 - 104.00 |
|---|---|
| 52wk Range: | 81.28 - 116.45 |
| Volume: | 5,587,088 |
| Avg Vol (3m): | 1,559,600 |
| Market Cap: | 30.20B |
| P/E (ttm): | 28.30 |
| EPS (ttm): | 3.58 |
| Div & Yield: | 0.20 (0.20%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Allergan Can Iron Out Its Wrinklesat Barrons.com(Thu 2:26PM EDT)
- AB InBev Is an Overweight and 3 More Analyst Upgrades To Knowat Wall St. Cheat Sheet(Thu 1:43PM EDT)
- Analysts: Buy United Technologies Now and 3 Other Research Notes to Check Outat Wall St. Cheat Sheet(Thu 1:31PM EDT)
- Regeneron Earnings Expected To Keep Boomingat Investor's Business Daily(Thu 1:21PM EDT)
- Analyst Moves: REGN, AGN, STXat Forbes(Thu 11:31AM EDT)
- Allergan Rises On Unusually High Volume (AGN)at TheStreet(Thu 11:18AM EDT)
- Alternative Dosage Forms Create Barriers Against Competition in Generics: A Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co.Wall Street Transcript(Thu 11:08AM EDT)
- Key Earnings this Weekat Motley Fool(Thu 10:16AM EDT)
- [video] Cramer's Six in 60: Allergan's Great Storyat CNBC(Thu 9:53AM EDT)
- Allergan price target lowered to $116 from $132 at Susquehannatheflyonthewall.com(Thu 8:44AM EDT)
- Allergan shares should be supported by earnings outlook, says Wells Fargotheflyonthewall.com(Thu 8:24AM EDT)
- Today's Market News To Trade On: 5 Stocks Moving On Newsat Seeking Alpha(Thu 8:11AM EDT)
- Cramer's Top Stock Picks: AVT TKR AGN REGNat TheStreet(Thu 6:00AM EDT)
- Why Allergan's Pain Is Regeneron's Gainat Motley Fool(Wed, May 1)
- Maker of Botox Plunges the Most in 13 Yearsat Bloomberg(Wed, May 1)
Press Releases
- Allergan Reports First Quarter 2013 Operating ResultsBusiness Wire(Wed, May 1)
- Allergan Announces Death of Stephen J. Ryan, M.D.Business Wire(Tue, Apr 30)
- Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for LEVADEX® (dihydroergotamine) New Drug ApplicationBusiness Wire(Tue, Apr 16)
Reports
- AGN: New Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- Thomson Reuters Stock Report - ALLERGAN, INC. (AGN-N)Thomson Reuters Stock Report(May 2)
- ValuEngine Detailed Valuation Report for AGNValuEngine, Inc.(May 2)